Liver transplantation from donor liver of organ donation after citizen's death: a single center experience
-
摘要:
目的 探讨公民逝世后器官捐献(器官捐献)供肝在临床肝移植中的应用效果。 方法 回顾性分析2011年10月至2016年12月在佛山市第一人民医院进行75例器官捐献肝移植的供、受者临床资料,对供者情况进行严格评估。总结肝移植受者的预后情况和并发症发生情况。 结果 75例肝移植受者1年累积存活率为88%,3年累积存活率为78%。9例受者死亡原因分别为移植术后肝癌复发转移4例、移植物抗宿主病1例、重症肺部感染1例、乙型病毒性肝炎(乙肝)复发肝衰竭1例、术后多器官功能衰竭1例、上消化道大出血1例。13例肝移植受体发生胆道狭窄,其中1例自行缓解,1例行经皮经肝胆管引流术(PTBD)治愈,11例行内镜下逆行性胰胆管造影术(ERCP)胆道内支架置入治疗,5例治愈,2例转行胆肠吻合术治疗治愈,4例仍在临床观察中。 结论 器官捐献供肝应用在临床肝移植中可取得良好的效果。对供体进行严格评估、受者围手术期规范管理、使用无肾上腺皮质激素免疫抑制维持方案、及时有效地处理并发症、术后定期随访是保证器官捐献供肝肝移植成功和受者长期生存的重要措施。 Abstract:Objective To evaluate the application value of donor liver from organ donation after citizen's death (organ donation) in clinical liver transplantation. Methods Clinical data of 75 pairs of donors and recipients undergoing liver transplantation from organ donation in the First People's Hospital of Foshan from October 2011 to December 2016 were retrospectively analyzed. The conditions of the donors were strictly evaluated. Clinical prognosis and the incidence of postoperative complications of the recipients were summarized. Results The 1-year and 3-year accumulated survival rates of 75 liver transplantation recipients were 88% and 78%. Four recipients died from the recurrence and metastasis of liver cancer, 1 case from graft-versus-host disease, 1 case from severe pulmonary infection, 1 case from recurrence of virus B hepatitis (hepatitis B) and liver failure, 1 case from postoperative multiple organ failure and 1 case from massive hemorrhage of the upper digestive tract. Thirteen recipients suffered from biliary tract stenosis. One case was mitigated spontaneously and 1 recipient was healed after percutaneous transhepatic biliary drainage (PTBD). Eleven cases were treated with endoscopic retrograde cholangiopancreatography (ERCP). Among them, 5 cases were healed, 2 recipients were switched to choledochojejunostomy and 4 cases were still monitored in clinical practice. Conclusions Liver transplantation from organ donation yields high clinical efficacy. Strict evaluation of donor conditions, standard perioperative management of the recipients, maintenance immunosuppressive therapy without adrenocortical hormone, timely and effective treatment of complications, regular postoperative follow-up are pivotal measures to guarantee the success of liver transplantation from organ donation and long-term survival of the recipients. -
[1] 中华医学会器官移植学分会.中国心脏死亡器官捐献工作指南(第2版)[J].中华器官移植杂志, 2011, 32(12): 756-758. DOI: 10.3760/cma.j.issn.0254-1785. 2011.12.014.Branch of Organ Transplantation of Chinese Medical Association. Guide of donation after cardiac death in China(2nd ed)[J]. Chin J Organ Transplant, 2011, 32(12): 756-758. DOI: 10.3760/cma.j.issn.0254-1785.2011.12.014. [2] 卫生部脑死亡判定标准起草小组.脑死亡判定标准(成人)(修订稿)[J].中国脑血管病杂志, 2009, 6(4): 220-224. DOI: 10.3969/j.issn.1672-5921.2009.04.014.The drafting group for brain death criteria of Ministry of Health of the People's Republic of China. Judgement standard of brain death (for adult) (revised edition)[J]. Chin J Cerebrovasc Dis, 2009, 6(4): 220-224. DOI: 10.3969/j.issn.1672-5921.2009.04.014. [3] Mancia C, Loustaud-Ratti V, Carrier P, et al. Controlled attenuation parameter and liver stiffness measurements for steatosis assessment in the liver transplant of brain dead donors[J]. Transplantation, 2015, 99(8): 1619-1624. DOI: 10.1097/TP.0000000000000652. [4] Flechtenmacher C, Schirmacher P, Schemmer P. Donor liver histology-a valuable tool in graft selection[J]. Langenbecks Arch Surg, 2015, 400(5): 551-557. DOI: 10.1007/s00423-015-1298-7. [5] Bertram S, Myland C, Swoboda S, et al. Liver steatosis in pre-transplant liver biopsies can be quantified rapidly and accurately by nuclear magnetic resonance analysis[J]. Virchows Arch, 2017, 470(2): 197-204. DOI: 10.1007/s00428-016-2047-1. [6] Zheng D, Guo Z, Schroder PM, et al. Accuracy of MR imaging and MR spectroscopy for detection and quantification of hepatic steatosis in living liver donors:a Meta-analysis[J]. Radiology, 2017, 282(1): 92-102. DOI: 10.1148/radiol.2016152571. [7] Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management[J]. Am J Transplant, 2015, 15(5): 1162-1172. DOI: 10.1111/ajt.13187. [8] Loggi E, Conti F, Cucchetti A, et al. Liver grafts from hepatitis B surface antigen-positive donors: a review of the literature[J]. World J Gastroenterol, 2016, 22(35): 8010-8016. DOI: 10.3748/wjg.v22.i35.8010. [9] Olthoff KM, Kulik L, Samstein B, et al. Validation ofa current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors[J]. Liver Transpl, 2010, 16(8): 943-949. DOI: 10.1002/lt.22091. [10] Kang WH, Hwang S, Song GW, et al. Acute graft-vs-host disease after liver transplantation: experience ata high-volume liver transplantation center in Korea[J]. Transplant Proc, 2016, 48(10): 3368-3372. DOI: 10.1016/j.transproceed.2016.08.051. [11] Ascha MS, Ascha ML, Hanouneh IA. Management of immunosuppressant agents following liver transplantation: less is more[J]. World J Hepatol, 2016, 8(3): 148-161. DOI: 10.4254/wjh.v8.i3.148. [12] Yoo MC, Vanatta JM, Modanlou KA, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction in 500 consecutive patients[J]. Transplantation, 2015, 99(6): 1231-1235. DOI: 10.1097/TP.0000000000000477. [13] Lerut JP, Pinheiro RS, Lai Q, et al. Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study[J]. Ann Surg, 2014, 260(5): 886-892. DOI: 10.1097/SLA.0000000000000969. [14] Sgourakis G, Dedemadi G. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review[J]. World J Gastroenterol, 2014, 20(31): 10703-10714. DOI: 10.3748/wjg.v20.i31.10703. [15] Wei Q, Xu X, Wang C, et al. Efficacy and safety ofa steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma[J]. Gut Liver, 2016, 10(4): 604-610. DOI: 10.5009/gnl15017. [16] Fung J, Chan SC, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B[J]. Am J Gastroenterol, 2013, 108(6): 942-948. DOI: 10.1038/ajg.2013.111. [17] Memeo R, Piardi T, Sangiuolo F, et al. Management of biliary complications after liver transplantation[J]. World J Hepatol, 2015, 7(29): 2890-2895. DOI: 10.4254/wjh.v7.i29.2890. [18] Tringali A, Barbaro F, Pizzicannella M, et al. Endoscopic management with multiple plastic stents of anastomotic biliary stricture following liver transplantation: long-term results[J]. Endoscopy, 2016, 48(6): 546-551. DOI: 10.1055/s-0042-100277.
点击查看大图
计量
- 文章访问数: 81
- HTML全文浏览量: 40
- PDF下载量: 9
- 被引次数: 0